

**VANCOUVER GENERAL HOSPITAL
CSU PHARMACEUTICAL SCIENCES
NON-FORMULARY DRUG DATA SHEET**

DRUG NAME Daptomycin	ALTERNATE NAME Cubicin®
--------------------------------	-----------------------------------

MANUFACTURER Oryx Pharmaceuticals Inc.

STRENGTH 500 mg / 10 mL vial	DOSAGE FORM Injection
----------------------------------------	---------------------------------

- INDICATIONS**
- Daptomycin is a cyclic lipopeptide that depolarizes the cell membrane potential
 - For the treatment of:
 - i) Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-resistant (MRSA) strains), *S. epidermidis*, *Streptococcus pyogenes*, *S. agalactiae*, and *Enterococcus sp.* (approved for vancomycin-susceptible strains only)
 - ii) *S. aureus* bloodstream infections (bacteremia) including those with right-sided native valve infective endocarditis caused by methicillin-susceptible and MRSA
 - Daptomycin is NOT indicated for pneumonia treatment due to limited alveolar penetration and surfactant inactivation

- RECONSTITUTION, STABILITY AND COMPATIBILITY**
- Reconstitute each vial with 10 mL NS by pointing needle to wall of vial to minimize foaming. Gently rotate vial to wet all powder. Stand for 10 minutes. Rotate vial to ensure complete reconstitution (50 mg/mL).
 - Reconstituted solution and prepared infusion bag are stable at RT for 12 hours or under refrigeration for 10 days.
 - Compatible with NS and lactated Ringer's. (Not compatible with dextrose containing diluents).
 - Do not administer with other medications in the same IV line (flush line before and after use if same line is being used for medications)

DOSAGE AND ADMINISTRATION

CrCl	Dosage Regimen	
	cSSSI	<i>S. aureus</i> bloodstream infections
≥ 30 mL/min	4 mg/kg IV q24h x 7-14 days	6 mg/kg IV q24h x 2-6 weeks
< 30 mL/min (HD & CAPD)	4mg/kg IV q48h x 7-14 days	6mg/kg IV q48h x 2-6 weeks

- IV direct – administer dose over 2 minutes
- IV intermittent – dilute dose in 50-100 mL NS and infuse over 30 minutes
- For hemodialysis patients, dose should be administered following dialysis on dialysis days

- KNOWN SIDE EFFECTS***
- Myopathy (muscular pains, weakness, and/or rhabdomyolysis with CPK elevations, neuropathy, constipation, nausea, injection site reactions, headache, diarrhea, hypersensitivity reactions (e.g. rash, pruritis))

- SPECIAL PRECAUTIONS**
- Elevations in CPK – monitor for muscle pain or weakness, and measure CPK weekly or more frequently in patients on a HMG-CoA reductase inhibitor or who have renal insufficiency
 - Potential drug interactions with HMG-CoA reductase inhibitors (consider holding while patient is on daptomycin) and warfarin (monitor INR for first few days)
 - Potential interaction with lab reagents for PT and INR testing, leading to false prolongation of PT or INR (minimize by drawing specimens right before next dose of daptomycin)
 - Daptomycin is latex free

***REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES**

Rev. Nov-2011